Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-08046037 + sasanlimab
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
PF-08046037 + sasanlimab is a combination investigational therapy developed by Pfizer for oncology indications. PF-08046037 is an antibody-drug conjugate (ADC) targeting PD-L1 and employs a Toll-like receptor 7 (TLR7) agonist as its payload, making it an immune-stimulating antibody conjugate (ISAC)[2][5]. Sasanlimab is a subcutaneously administered anti-PD-1 monoclonal antibody checkpoint inhibitor that is being developed for use in various cancers, including bladder cancer, lung cancer, and head and neck cancer[1][2][7]. The combination is designed to enhance antitumor immunity through simultaneous blockade of PD-1 and direct immune stimulation via TLR7 agonism. PF-08046037 + sasanlimab is currently being studied in phase 1 trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and head and neck cancer[2][5].
- Other names
- PF-08046037 plus sasanlimabPF08046037 plus sasanlimabPF 08046037 plus sasanlimab
02
Targets
TLR7 (Toll-like receptor 7)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on PF-08046037 + sasanlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-08046037 + sasanlimab.